- Home
- MVST vs INBX Comparison
MVST vs INBX Comparison
Compare MVST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 999.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | MVST | INBX |
|---|---|---|
| Price | $1.42 | $106.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 3.1M | 509.2K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $17.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $1.37 | $12.80 |
| 52 Week High | $7.12 | $155.29 |
Technical Indicators
Market Signals| Indicator | MVST | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 48.58 |
| Support Level | N/A | $69.30 |
| Resistance Level | $2.49 | $155.29 |
| Average True Range (ATR) | 0.14 | 13.09 |
| MACD | -0.02 | -2.08 |
| Stochastic Oscillator | 16.66 | 14.74 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.